Harpoon Therapeutics jumps on positive interim data in blood cancer trial

Harpoon Therapeutics

12/12/2022 15:58

(Updates)
    ** Shares of Harpoon Therapeutics Inc  HARP.O  more than
double at $2.70, the biggest pct gainer across the U.S. stock
exchanges 
    ** The drug developer reported late on Sunday updated
positive interim data from early-stage experimental treatment -
HPN217 - for relapsed/recurring blood cancer that affects plasma
cells
    ** HPN217 showed continued evidence of clinical activity and
a tolerable safety profile in 62 heavily pre-treated patients -
Harpoon 
    ** Co says trial expected to reach completion in the first
half of 2023
    ** Including session's gain, stock down 64.9% YTD
 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com))